The impact of the IDEAS study on patient management

Gil Rabinovici, MD from the Memory and aging Center, University of California, San Francisco, CA provides an overview of his work on the impact of amyloid PET on patient management. This IDEAS study is testing the ability of PET scans to detect amyloid protein and improve Alzheimer’s diagnosis in 18,000 Medicare beneficiaries. Here Dr Rabinovici provides data from the first 4000 patients of the study which has shown how PET scanning is able to diagnose Alzheimer’s in diagnostically uncertain patients. The data so far shows significant evidence on how PET scans has led to more specific diagnoses of Alzheimer’s, and hence patient management is also adjusted according to PET scan results. By underutilising PET scans, diagnostically uncertain patients will not get the best possible treatment, ultimately providing suboptimal care. This video was recorded at the press briefing at the Alzheimer’s Association International Conference (AAIC) 2017, London, UK

Share this video